Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 2
2014 3
2015 4
2016 12
2017 16
2018 26
2019 25
2020 25
2021 0
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 33384315

99 results
Results by year
Filters applied: . Clear all
Page 1
The role of SGLT-2 inhibitors in managing type 2 diabetes.
Tsushima Y, Lansang MC, Makin V. Tsushima Y, et al. Cleve Clin J Med. 2020 Dec 31;88(1):47-58. doi: 10.3949/ccjm.88a.20088. Cleve Clin J Med. 2020. PMID: 33384315 Free article.
Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y. Handelsman Y. Adv Ther. 2019 Oct;36(10):2567-2586. doi: 10.1007/s12325-019-01054-w. Epub 2019 Aug 23. Adv Ther. 2019. PMID: 31444707 Free PMC article. Review.
The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
Woo V, Connelly K, Lin P, McFarlane P. Woo V, et al. Curr Med Res Opin. 2019 Jul;35(7):1283-1295. doi: 10.1080/03007995.2019.1576479. Epub 2019 Feb 15. Curr Med Res Opin. 2019. PMID: 30767677 Review.
The Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit.
Patel DK, Strong J. Patel DK, et al. Diabetes Ther. 2019 Oct;10(5):1771-1792. doi: 10.1007/s13300-019-00686-z. Epub 2019 Aug 27. Diabetes Ther. 2019. PMID: 31456166 Free PMC article. Review.
Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
Weir MR. Weir MR. Postgrad Med. 2019 Aug;131(6):367-375. doi: 10.1080/00325481.2019.1624582. Epub 2019 Jun 5. Postgrad Med. 2019. PMID: 31132013
Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
Schwartz SS, Ahmed I. Schwartz SS, et al. Curr Med Res Opin. 2016 May;32(5):907-19. doi: 10.1185/03007995.2016.1151774. Epub 2016 Feb 26. Curr Med Res Opin. 2016. PMID: 26854518 Review.
Sodium-glucose Cotransporter 2 Inhibitors: Potential Cardiovascular and Mortality Benefits.
Lovic D, Pittaras A, Kallistratos M, Tsioufis C, Grassos C, Djordjevic D, Tasic I, Manolis A. Lovic D, et al. Cardiovasc Hematol Disord Drug Targets. 2018;18(2):114-119. doi: 10.2174/1871529X18666180227102137. Cardiovasc Hematol Disord Drug Targets. 2018. PMID: 29485012 Review.
Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?
Rajasekeran H, Cherney DZ, Lovshin JA. Rajasekeran H, et al. Curr Opin Nephrol Hypertens. 2017 Sep;26(5):358-367. doi: 10.1097/MNH.0000000000000343. Curr Opin Nephrol Hypertens. 2017. PMID: 28582367 Review.
Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.
Mende CW. Mende CW. Curr Med Res Opin. 2017 Mar;33(3):541-551. doi: 10.1080/03007995.2016.1271779. Epub 2017 Jan 4. Curr Med Res Opin. 2017. PMID: 27977314 Review.
Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease.
Aftab S, Vetrivel Suresh R, Sherali N, Daniyal M, Tsouklidis N. Aftab S, et al. Cureus. 2020 Oct 3;12(10):e10783. doi: 10.7759/cureus.10783. Cureus. 2020. PMID: 33042651 Free PMC article. Review.
99 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page